This keynote presentation delves into the comprehensive analysis of the TORREY Phase 2 study focused on Seralutinib for Pulmonary Arterial Hypertension (PAH). The talk will cover the study's background, objectives, methodologies, and the findings concerning safety and efficacy metrics over a 72-week period. Insights into the physiological and clinical improvements, as well as the study's implications for long-term PAH management and future research directions, will be explored. Attendees will...